KRAS and cancer: The RAS-regulated ERK1/2 signalling pathway is frequently activated in cancer [6] and developmental syndromes (RASopathies) [7,8] due to activating mutations in a variety of pathway components including the RAS proteins (especially KRAS), BRAF, CRAF, MEK1 and MEK2.